Why the study?
Several unmet needs persist in the diagnosis and management of patients with IC-MPGN and C3G due to their rarity and overlapping clinical, histologic, and pathophysiologic features.
This review emphasizes the need for a multidisciplinary approach and improved understanding of underlying mechanisms to optimize targeted treatments for IC-MPGN and C3G.
Case series highlights diagnostic challenges in IC-MPGN/C3G; leaves optimal targeted therapies open for prospective trials.
Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) and complement 3 glomerulopathy (C3G) are rare, complement-mediated kidney diseases, previously classified under the group of kidney disorders termed membranoproliferative glomerulonephritis (MPGN) type 1, type 2, and type 3. Despite new advances in our understanding of IC-MPGN and C3G, several unmet needs persist in the diagnosis and management of patients with these nephropathies, due in part to their rarity and their overlapping clinical presentations, histologic features, and underlying pathophysiologies. This review summarizes our current understanding of the role of complement in IC-MPGN and C3G, and underlines the key histopathologic differences between the diseases. Using seven illustrative patient cases, we discuss consensus guideline treatment recommendations and the uncertainties, challenges, and considerations regarding the diagnosis and management of patients with IC-MPGN and C3G in clinical practice. The presented cases emphasize the need for a multidisciplinary approach encompassing primary care providers (PCPs), nephrologists, nephropathologists, and laboratory scientists. Key knowledge gaps are evaluated, including differential diagnoses, underlying pathologic mechanisms, and the lack of effective treatments targeting drivers of disease. As the therapeutic landscape evolves, an improved understanding of IC-MPGN and C3G is crucial to identifying optimal targeted-treatment strategies and facilitating a personalized approach to the management of these complex glomerular diseases.
No takes yet. Share an insight, caveat, or question.
Bomback et al. (2024) conducted a review in Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) and complement 3 glomerulopathy (C3G) (n=7).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: